Albumedix Ltd. Appoints Mark Kalinowski as Chief Financial Officer

PRESS RELEASE: Nottingham, UK, 2^nd August 2021 – Albumedix Ltd. (‘Albumedix’), a globally recognized leader in albumin-based enabling solutions for advanced therapies and next-generation biopharmaceuticals, announced today the appointment of Mark Kalinowski as Chief Financial Officer, effective as of August 2^nd, 2021.   

Mark Kalinowski is an accomplished CFO with a wealth of experience in B2B service and manufacturing industries, with a background in financial and general management within multi-site operations across Europe and Asia. Mark joins Albumedix to oversee the company’s corporate function and will become a key member of executive management reporting directly to Albumedix’ Chief Executive Officer, Jonas Skjødt Møller.

Mark will succeed Andy Thorpe, who will step down as CFO/FD after 25 years’ service with the company and transition into a non-executive director role at the Board of Albumedix.

Commenting on the appointment, Jonas Skjødt Møller, said “We are delighted to have Mark join the team as we continue to realise our ambitious growth strategy. His extensive financial and commercial experience combined with his impeccable track record in building and maintaining partner relationships will make him a valuable executive as we continue investing in our manufacturing and innovation capabilities.” He additionally commented: “I’d also like to take this opportunity to thank Andy for his incredible contribution to Albumedix over so many years. I am thrilled that Andy will be continuing in a Board Member capacity, enabling us to keep his wealth of knowledge and experience in shaping Albumedix’ future.”

Prior to joining Albumedix, Mark held senior leadership positions with Thyssenkrupp Elevators, CPL Aromas and Triumph Motorcycles with responsibilities spanning finance, operations, commercial and procurement.

Commenting on his new appointment, Mark said: “It is with real excitement and pride that I join such a reputable and established business as Albumedix. I am very much looking forward to sharing my experience gained from other industries with the team and supporting the company’s continued success.”

Mark qualified as a Chartered Management Accountant from Derby University, whilst being sponsored by GEC Turbine Generators gaining first-hand industrial experience.

About Albumedix – Dedicated to better Health 

Albumedix is a science-driven, life-science company focused on enabling the creation of superior biopharmaceuticals utilizing our recombinant human albumin products. We believe in empowering excellence to enable advanced therapies and facilitate otherwise unstable drug candidates reach patients worldwide. We are proud to be recognized as the world leader in recombinant human albumin with products and technologies used in clinical and marketed drugs by pharmaceutical and medical device companies worldwide. Headquartered in Nottingham, England with more than 100 people all committed to improving patient quality of life. We are just as passionate about albumin and albumin-enabled therapies today as we were when we started more than 35 years ago. Learn more today.

For media enquiries, please contact:

Sian Gilfillan, Marketing and Communications Manager, BD@albumedix.com